David A. Siegel Verve Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 293,200 shares of VERV stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
293,200
Previous 184,600
58.83%
Holding current value
$2.49 Million
Previous $893,000
85.11%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$105 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$58.6 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$56.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$34 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$33.9 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $509M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...